MyMD Pharmaceuticals Files Definitive Proxy Statement

TL;DR

MyMD Pharma (MYMD) filed its DEF 14A proxy statement. Standard shareholder vote stuff.

AI Summary

MyMD Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on July 1, 2024. The filing concerns the company's proxy materials, which are used to solicit votes from shareholders for upcoming meetings. MyMD Pharmaceuticals, previously known as Akers Biosciences, Inc., is incorporated in Delaware and has its principal business address in Baltimore, MD.

Why It Matters

This filing is a standard regulatory requirement for public companies to communicate with shareholders about important matters requiring a vote, such as board elections or corporate actions.

Risk Assessment

Risk Level: low — A DEF 14A filing is a routine disclosure and does not inherently represent a change in the company's risk profile.

Key Players & Entities

• MyMD Pharmaceuticals, Inc. (company) — Registrant
• Akers Biosciences, Inc. (company) — Former Company Name
• 20240701 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — shares of: our common stock, par value $0.001 per share (the “Common Stock&rdqu

Filing Documents

• formdef14a.htm (DEF 14A) — 374KB
• formdef14a_001.jpg (GRAPHIC) — 27KB
• proxy_001.jpg (GRAPHIC) — 248KB
• proxy_002.jpg (GRAPHIC) — 163KB
• 0001493152-24-025840.txt ( ) — 979KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Materials under §240.14a-12 MyMD Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) N/A (Names of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (check the appropriate box): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 (856) 848-8698 July 1, 2024 To the Stockholders of MyMD Pharmaceuticals, Inc.: You are cordially invited to attend a special meeting (the “Special Meeting”) of the stockholders of MyMD Pharmaceuticals, Inc. (the “Company”), to be conducted in a virtual format only via live audio webcast at 10:00 a.m. Eastern Time, on Wednesday, July 24, 2024, at www.virtualshareholdermeeting.com/MYMD2024SM . In order to facilitate stockholder attendance and participation by enabling stockholders to participate from any location at no cost, this Special Meeting will be conducted in a virtual format only. Stockholders will not be able to attend the Special Meeting in person; however, stockholders of record will be able to participate, vote electronically and submit questions during the live webcast of the Special Meeting by visiting www.virtualshareholdermeeting.com/MYMD2024SM and entering the 16-digit control number found on the enclosed proxy card or voting form. If you encounter any difficulties accessing the virtual Special Meeting, please call the technical support number available on the virtual meeting page on the morning of the Special Meeting. Your vote is very important, regardless of the number of shares of our voting securities that you own. Whether or not you expect to be present at the Special Meeting, after receiving the proxy materials, please vote as promptly as possible to ensure your representation and the presence of a quorum at the Special Meeting. As an alternative to voting during the Special Meeting, you may vote via the Internet or telephone or by signing, dating, and returning the enclosed proxy card or voting form. If your shares are held in the name of a broker, trust, bank or other nominee, and you receive these materials through your broker or through another intermediary, please complete and return the materials in accordance with the instructions provided to you by such broker or other intermediary or contact your broker directly in order to obtain a proxy issued to you by your nominee holder to attend the meeting and vote electronically. Failure to do so may result in your shares not being eligible to be voted by proxy at the Special Meeting. On behalf of the Board of Directors, I urge you to submit your vote as soon as possible, even if you currently plan to attend the meeting. Thank you for your support of our company. I look forward to seeing you at the virtual Special Meeting. By Order of the Board, /s/ Joshua Silverman Joshua Silverman Chairman of the Board of Directors July 1, 2024 Important Notice Regarding The Availability Of Proxy Materials For The STOCKholder Meeting To Be Held On Wednesday, July 24, 2024: Our official Notice of Special Meeting of Stockholders and Proxy Statement are available at: www.proxyvote.com . MyMD Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 (856) 848-8698 Notice of Special Meeting of Stockholders to be Held on July 24, 2024 The special meeting (the “Special Meeting”) of the stockholders of MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), will be held at 10:00 a.m. Eastern Time, on Wednesday, July 24, 2024, in a virtual format only via live audio website at www.virtualshareholdermeeting.com/MYMD2024SM . We will consider and act on the following items of business at the Special Meeting: 1. A proposal to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying (i) shares of Series F-1 convertible preferred stock and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated as of May 20, 2024, by and among the Company and the investors named therein (the “Series F-1 Purchase Agreement”), in an amount equal to or in excess of 20% of our common stock outstanding immediately prior to the issuance of such Series F-1 convertible preferred stock and warrants (including any amortization payments made to the holders of th

View Full Filing

View this DEF 14A filing on SEC EDGAR